Eblasakimab

A4DAB095 | Phase-II

Target IL13RA1/CD213A1

Isotype / Subclass G4 / None

Company

ASLAN Pharmaceuticals

Clinical Status Phase-II

Format Whole mAb

Synonyms

ASLAN 004 ASLAN-004 ASLAN004 CSL 334 CSL334 CSL-334 MK 6105 MK6105 MK-6105

pH Formulation —

IMGT PubChem (443565724) PubChem (458923805) PubChem (472422539) PubChem (485482300) PubChem (485511940) Thera-SAbDab YAbS

Avg A4D Score

-0.6957

Score Range

-0.7 to -0.69

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB095_4hwb_H_L	4hwb	97%	-0.7023	6.5	9.0	-0.2865	-0.7477
A4DAB095_4hwe_H_L	4hwe	97%	-0.6891	6.5	9.0	-0.2604	-0.7364